^
Association details:
Biomarker:SYNE1 mutation
Cancer:Clear Cell Renal Cell Carcinoma
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients

Published date:
10/08/2020
Excerpt:
To evaluate the ability of SYNE1 mutation to serve as a biomarker predictive of the clinical response to ICB therapy, we analyzed datasets from patients with stage 4 ccRCC using the TIDE algorithm. The results showed that the mt group was associated with lower TIDE scores, indicating a stronger response to ICB therapy....These findings suggest SYNE1 mutations may play a role in ICB therapy in ccRCC.
DOI:
10.18632/aging.103781